Skip to main content

Advertisement

SpringerLink
Log in

Use of biologics in the treatment of childhood rheumatic diseases

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Over the last two decades, progression in the knowledge of molecular biologic techniques has led to a better understanding of immunopathogenesis and identification of several cytokines, which propagate chronic arthritis in both adult and pediatric patients. A number of biologic agents have been developed in targeting different immune markers or mediators with the hope that they may help in controlling the inflammation in the group of patients who are resistant to disease-modifying antirheumatic drugs (DMARDs) and may alter the natural history of the diseases. Tumor necrosis factor (TNF)-a is the first to be targeted and its antagonists have been approved. Other biologic agents targeting different markers/mediators have followed and have been tested in clinical trials especially in adult rheumatoid arthritis (RA). Experiences in pediatric use are limited and agents proved to be effective in adult RA are not always transferred the same efficacy in different subtypes of juvenile idiopathic arthritis (JIA). It is reasonable to see the efficacy, and more importantly the safety profiles of each agent before the decision is made to use them in children. This article reviews the published and anecdotal reports of biologic agents that have been used in children with JIA and also focuses on the potential use of other biologic agents in JIA that have been used in trials to combat adult RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Laxer RM: Long-term toxicity of immune suppression in juvenile rheumatic diseases. Rheumatology 1999, 38:743–746. This article gives the details in immunosuppressive agent toxicity in the treatment of childhood rheumatic diseases and insights in the need for safety with better efficacy agents.

    Article  PubMed  CAS  Google Scholar 

  2. Petty RE: Prognosis in children with rheumatic diseases: justification for consideration of new therapies. Rheumatology 1999, 38:739–742.

    Article  PubMed  CAS  Google Scholar 

  3. Lovell DJ, Giannini EH, Reiff A, et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis: Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000, 342(11):763–769. This article is the first collaborative study that evaluates the safety and efficacy of etanercept in polyarticular JIA. The study involved 69 patients with polyarthritis of any types and showed significant improvement in patients with active polyarticular JIA and the agent was well tolerated with mild side effects.

    Article  PubMed  CAS  Google Scholar 

  4. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998, 25(10):1991–1994.

    PubMed  CAS  Google Scholar 

  5. Prieur AM, Kaufmann MT, Griscelli C, et al.: Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet 1987, 2(8570):1240–1242.

    Article  PubMed  CAS  Google Scholar 

  6. Grom AA, Murray KJ, Luyrink L, et al.: Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy. Arthritis Rheum 1996, 39(10):1703–1710.

    Article  PubMed  CAS  Google Scholar 

  7. Eberhard BA, Laxer RM, Andersson U, et al.: Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis. Clin Exp Immunol 1994, 96(2):260–266.

    Article  PubMed  CAS  Google Scholar 

  8. Rooney M, David J, Symons J, et al.: Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995, 34(5):454–460.

    Article  PubMed  CAS  Google Scholar 

  9. De Benedetti F, Pignatti P, Gerloni V, et al.: Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J Rheumatol 1997, 24(7):1403–1409.

    PubMed  Google Scholar 

  10. Lepore L, Pennesi M, Saletta S, et al.: Study of IL-2, IL-6, TNF alpha, IFN gamma and beta in the serum and synovial fluid of patients with juvenile chronic arthritis. Clin Exp Rheumatol 1994, 12(5):561–565.

    PubMed  CAS  Google Scholar 

  11. De Benedetti F, Massa M, Pignatti P, et al.: Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest 1994, 93(5):2114–2119.

    PubMed  Google Scholar 

  12. De Benedetti F, Robbioni P, Massa M, et al.: Serum interleukin-6 levels and joint involvement in polyarticular and pauciarticular juvenile chronic arthritis. Clin Exp Rheumatol 1992, 10(5):493–498.

    PubMed  Google Scholar 

  13. de Benedetti F, Massa M, Robbioni P, et al.: Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis [comments]. Arthritis Rheum 1991, 34(9):1158–1163.

    Article  PubMed  Google Scholar 

  14. Brozik M, Rosztoczy I, Meretey K, et al.: Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production [comments]. J Rheumatol 1992, 19(1):63–68.

    PubMed  CAS  Google Scholar 

  15. Moreland LW, Heck LW Jr., Koopman, WJ: Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum 1997, 40(3):397–409. The author summarized the current understanding of cytokines in the pathogenesis of RA and the experiences from several biologic agent trials in adult RA.

    Article  PubMed  CAS  Google Scholar 

  16. Kavanaugh AF: Anti-tumor necrosis factor-alpha monoclonal antibody therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998, 24(3):593–614.

    Article  PubMed  CAS  Google Scholar 

  17. de Benedetti F, Pignatti P, Massa M, et al.: Soluble tumour necrosis factor receptor levels reflect coagulation abnormalities in systemic juvenile chronic arthritis. Br J Rheumatol 1997, 36(5):581–588.

    Article  PubMed  Google Scholar 

  18. Moreland LW, Baumgartner SW, Schiff MH, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [Comments]. N Engl J Med 1997, 337(3):141–147.

    Article  PubMed  CAS  Google Scholar 

  19. Moreland LW: Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis. Rheum Dis Clin North Am 1998, 24(3):579–591.

    Article  PubMed  CAS  Google Scholar 

  20. Moreland L, Cohen S, Baumgartner S, et al.: Long-term use of etanercept in patients with DMARD-refractory rheumatoid arthritis. Arthritis Rheum 1999, 42(S9):S401.

    Google Scholar 

  21. Weiblatt M, Kremer J, Lange M, et al.: Long-term safety and efficacy of combination therapy with methotrexate and etanercept (Enbrel). Arthritis Rheum 1999, 42(S9):S401.

    Google Scholar 

  22. Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate [Comments]. N Engl J Med 1999, 340(4):253–259.

    Article  PubMed  CAS  Google Scholar 

  23. Kavanaugh A, Schaible T, DeWoody K, et al.: Long-term follow-up of patients treated with infliximab (anti-TNFa antibody) in clinical trials. Arthritis Rheum 1999, 42(S9):S401.

    Google Scholar 

  24. Lipsky P, St Clair W, Furst D, et al.: 54-week clinical and radiographic results from the ATTRACT trial: a phase III study of infliximab (Remicade) in patients with active RA despite methotrexate. Arthritis Rheum 1999, 42(S9):S401.

    Google Scholar 

  25. Maini RN, Breedveld FC, Kalden JR, et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis [Comments]. Arthritis Rheum, 1998, 41(9):1552–1563.

    Article  PubMed  CAS  Google Scholar 

  26. Elliott MJ, Woo P, Charles P, et al.: Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). Br J Rheumatol 1997, 36(5):589–93.

    Article  PubMed  CAS  Google Scholar 

  27. Arend WP, Dayer JM: Cytokines and cytokine receptors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990, 33(3):305–312. The article reviewed the biologic effects of IL-1 and TNF-a in the pathogenesis of RA and the strategies for the development of respective antagonists for RA therapy.

    Article  PubMed  CAS  Google Scholar 

  28. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist [see comments]. Arthritis Rheum 1998, 41(12):2196–2204.

    Article  PubMed  CAS  Google Scholar 

  29. Bresnihan B, Cunnane G: Interleukin-1 receptor antagonist. Rheum Dis Clin North Am 1998, 24(3):615–628. This review article discusses the current understanding of IL-1RA biologic effect in RA. The author summarized the results of existing clinical trials and future direction in terms of the use of this biologic agent in RA therapy.

    Article  PubMed  CAS  Google Scholar 

  30. Martini A, Ravelli A, Notarangelo LD, et al.: Enhanced interleukin 1 and depressed interleukin 2 production in juvenile arthritis. J Rheumatol 1986, 13(3):598–603.

    PubMed  CAS  Google Scholar 

  31. De Benedetti F, Pignatti P, Massa M, et al.: Circulating levels of interleukin 1 beta and of interleukin 1 receptor antagonist in systemic juvenile chronic arthritis. Clin Exp Rheumatol 1995, 13(6):779–784.

    PubMed  Google Scholar 

  32. Muller K, Zak M, Nielsen S, et al.: Interleukin-1 receptor antagonist in neonates, children and adults, and in patients with pauci- and polyarticular onset juvenile chronic arthritis. Clin Exp Rheumatol 1997, 15(4):439–444.

    PubMed  CAS  Google Scholar 

  33. Madson KL, Moore TL, Lawrence JM 3rd, et al.: Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis. J Rheumatol 1994, 21(12):2359–2563.

    PubMed  CAS  Google Scholar 

  34. Kutukculer N, Caglayan S, Aydogdu F: Study of pro-inflammatory (TNF-alpha, IL-1alpha, IL-6) and T-cell-derived (IL-2, IL-4) cytokines in plasma and synovial fluid of patients with juvenile chronic arthritis: correlations with clinical and laboratory parameters. Clin Rheumatol 1998, 17(4):288–292.

    Article  PubMed  CAS  Google Scholar 

  35. Donn RP, Farhan AJ, Barrett JH, et al.: Absence of association between interleukin 1 alpha and oligoarticular juvenile chronic arthritis in UK patients. Rheumatology (Oxford) 1999, 38(2):171–175.

    Article  CAS  Google Scholar 

  36. De Benedetti F, Martini A: Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? [editorial]. J Rheumatol 1998, 25(2):203–207.

    PubMed  Google Scholar 

  37. Fishman D, Faulds G, Jeffery R, et al.: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998, 102(7):1369–1376.

    Article  PubMed  CAS  Google Scholar 

  38. Keul R, Heinrich PC, Muller-newen G, et al.: A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 1998, 10(9):729–734.

    Article  PubMed  CAS  Google Scholar 

  39. Muller-Newen G, Kuster A, Hemmann U, et al.: Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 1998, 161(11):6347–6355.

    PubMed  CAS  Google Scholar 

  40. Wendling D, Racadot E, Wijdenes J: Treatment of severe rheumatoid arthritis by anti-interleukin-6 monoclonal antibody. J Rheumatol 1993, 20:259–262.

    PubMed  CAS  Google Scholar 

  41. Coto C, Varela G, Hernandez V, et al.: Use of recombinant interferon gamma in pediatric patients with advanced juvenile chronic arthritis. Biotherapy 1998, 11(1):15–20.

    Article  PubMed  CAS  Google Scholar 

  42. Keystone E, Wherry J and Grint P, IL-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheu Dis Clin North Am 1998, 24(3):629–639.

    Article  CAS  Google Scholar 

  43. Murray KJ, Grom AA, Thompson SD, et al.: Contrasting cytokine profiles in the synovium of different forms of juvenile rheumatoid arthritis and juvenile spondyloarthropathy: prominence of interleukin 4 in restricted disease. J Rheumatol 1998, 25(7):1388–1398.

    PubMed  CAS  Google Scholar 

  44. Moreland L, Chase W, Fife R, et al.: Phase I/II study evaluating the safety and potential efficacy of recombinant interleukin-11 in patients with refractory rheumatoid arthritis. Arthritis Rheum 1999, 42(S9):S170.

    Google Scholar 

  45. Barbadillo C, G-Arroyo A, Salas C, et al.: Anti-integrin immunotherapy in rheumatoid arthritis: protective effect of anti-a4 antibody in adjuvant arthritis. Springer Semin Immunopathol 1995, 16:427–436.

    Article  PubMed  CAS  Google Scholar 

  46. Jasin HE, Lightfoot E, Davis LS, et al.: Amelioration of antigen-induced arthritis in rabbit tested with monoclonal antibodies to leukocyte adhesion molecule. Arthritis Rheum 1992, 35:541–549.

    PubMed  CAS  Google Scholar 

  47. Bloom BJ, Miller LC, Tucker LB, et al.: Soluble adhesion molecules in juvenile rheumatoid arthritis [In Process Citation]. J Rheumatol 1999, 26(9):2044–2048.

    PubMed  CAS  Google Scholar 

  48. Laucella SA, Gaddi E, Balbaryski J, et al.: Soluble intercellular adhesion molecule-1 in paediatric connective tissue diseases. Acta Paediatr 1999, 88(4):399–403.

    Article  PubMed  CAS  Google Scholar 

  49. Bloom B, Nelson S, Alario A, et al.: Soluble adhesion molecule level in synovial fluid of children with juvenile chronic arthritis. Arthritis Rheum 1999, 42(S9):S395.

    Google Scholar 

  50. Kavanaugh AF, Davis LS, Nichols LA, et al.: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 1994, 37(7):992–999.

    Article  PubMed  CAS  Google Scholar 

  51. Kavanaugh AF, Schulze-Koops H, Davis LS, et al.: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 1997, 40(5):849–853.

    Article  PubMed  CAS  Google Scholar 

  52. Barnett ML, Kremer JM, St Clair EW, et al.: Treatment of rheumatoid arthritis with oral type II collagen. Arthritis Rheum 1998, 41(2):290–297.

    Article  PubMed  CAS  Google Scholar 

  53. Barnett ML, Combitchi D, Trentham DE: A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39(4):623–628.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pediatric Rheumatology, The Hospital for Special Surgery, 535 East 70th Street, 10021, New York, NY, USA

    Thaschawee Arkachaisri MD & Thomas J. A. Lehman MD, FAAP, FACR

Authors
  1. Thaschawee Arkachaisri MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. A. Lehman MD, FAAP, FACR
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arkachaisri, T., Lehman, T.J.A. Use of biologics in the treatment of childhood rheumatic diseases. Curr Rheumatol Rep 2, 330–336 (2000). https://doi.org/10.1007/s11926-000-0071-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-000-0071-1

Keywords

Search

Navigation